ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cole, S.T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cole, S.T.
Eur Respir J 2002; 20:78S-86S
Copyright ©ERS Journals Ltd 2002


Comparative mycobacterial genomics as a tool for drug target and antigen discovery

S.T. Cole

CORRESPONDENCE: S.T. Cole, Unité de Génétique Moléculaire Bactérienne, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France. Fax: 33 140613583. E-mail: stcole@pasteur.fr

Keywords: drug targets, functional genomics, genomics, leprosy, tuberculosis

Received: January 28, 2002
Accepted March 13, 2002

Genomics and the associated downstream technologies are generating vast data sets that provide new opportunities for understanding and combating both infectious and genetic diseases in humans.

The genomic approach has been applied to tuberculosis, a major cause of transmissible morbidity and mortality, with notable success. Complete genome sequences are now available for three members of the Mycobacterium tuberculosis complex and the related intracellular pathogen M. leprae.

Many of the predictions generated in silico by genomics have been validated through functional analysis, including studies of the transcriptome and proteome, and led to the identification of essential genes. Knowledge of the latter defines potential targets for new and existing drugs and their specificity can be assessed by comparative genomics with the host or other pathogens. Genomics is also furthering tuberculosis vaccine development by pinpointing potentially antigenic proteins as well as providing better diagnostic tools to detect infection.




This article has been cited by other articles:


Home page
Infect. Immun.Home page
B. Sidders, C. Pirson, P. J. Hogarth, R. G. Hewinson, N. G. Stoker, H. M. Vordermeier, and K. Ewer
Screening of Highly Expressed Mycobacterial Genes Identifies Rv3615c as a Useful Differential Diagnostic Antigen for the Mycobacterium tuberculosis Complex
Infect. Immun., September 1, 2008; 76(9): 3932 - 3939.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. M. Talaat and K. Stemke-Hale
Expression Library Immunization: a Road Map for Discovery of Vaccines against Infectious Diseases
Infect. Immun., November 1, 2005; 73(11): 7089 - 7098.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the European Respiratory Society.